Skip to content

Ibogaine research published in 2018

22 studies whose primary subject is ibogaine were published in 2018, up from 11 in 2017. Newest first. Back to the ibogaine overview

Studies

Effects of ibogaine per os application on redox homeostasis in rat liver and erythrocytes

Archives of Biological Sciences December 5, 2018 Teodora Vidonja Uzelac, Nikola Tatalović, Milica Mijović et al. 7 citations

Ibogaine, administered as a single oral dose (1-25 mg/kg body weight), has been used as an addiction-interrupting agent. Its effects persist for up to 72 h. Ex vivo results showed that ibogaine induced cellular energy consumption and restitution, followed by increased reactive oxygen species production and antioxidant activity. Therefore, the aim of this work was to explore the effect of a...

DOI: 10.2298/abs180918055v (opens in new tab) Oxidative stress Pharmacology Superoxide dismutase Glutathione peroxidase +8

Hallucinogen Persisting Perception Disorder After Ibogaine Treatment for Opioid Dependence.

Journal of Clinical Psychopharmacology December 1, 2018 Thomas Knuijver, Maarten Belgers, Wiebren Markus et al.

expressed in brain regions associated with emotional processing. Modulation of the hypothalamic-pituitary-adrenal axis by altering cortisol tone also seems to be involved in this effect. The ECS modulates stress and anxiety. Serum AEA and 2-AG levels are increased after stress, and AEA levels are negatively associated to baseline anxiety and are significantly reduced in womenwith major...

Ibogaine Modifies GDNF, BDNF and NGF Expression in Brain Regions Involved in Mesocorticolimbic and Nigral Dopaminergic Circuits

ChemRxiv October 29, 2018 Soledad Marton, Bruno González, Sebastián Rodríguez et al. preprint

Ibogaine is a psychedelic alkaloid which has been subject of intense scientific research due to its reported ability to attenuate drug-seeking behavior. Recent work suggested that ibogaine effects on alcohol self-administration in rats was related to the release of Glial Cell Derived Neurotrophic Factor (GDNF) in the Ventral Tegmental Area (VTA), a mesencephalic region which hosts soma of...

DOI: 10.26434/chemrxiv.7261559 (opens in new tab) Ventral tegmental area Neurotrophic factors Dopaminergic Nucleus accumbens +5

Phytochemical characterization of Tabernanthe iboga root bark and its effects on dysfunctional metabolism and cognitive performance in high-fat-fed C57BL/6J mice

Journal of Food Bioactives September 30, 2018 Bayissi Bading-Taïka, Tunde Akinyeke, Armando Alcazar Magana et al. 14 citations

Preparations of the root bark of Tabernanthe iboga have long been used in Central and West African traditional medicine to combat fatigue, as a neuro-stimulant in rituals, and for treatment of diabetes. The principal alkaloid of T. iboga, ibogaine, has attracted attention in many countries around the world for providing relief for opioid craving in drug addicts. Using a plant metabolomics...

DOI: 10.31665/jfb.2018.3154 (opens in new tab) Full text (opens in new tab) Phytochemical Bark sound Traditional medicine Pharmacology

Bwiti, iboga, trance and healing in Gabon

Mental Health, Religion & Culture September 14, 2018 Pierre Didier Nyongo Ndoua, Kaveh Vaghar

ABSTRACT The Bwiti is one out of several religions in Africa and through it, it is believed, that the members can be connected to the world of the ancestors. There is also the ritual of healing in Bwiti. In this ritual, participants are invited to take iboga. They fall into a trance and after this phase, which in principle lasts three days; those who were sick recover the health in many cases....

DARK Classics in Chemical Neuroscience: Ibogaine

ACS Chemical Neuroscience September 14, 2018 Michael Wasko, Paula A. Witt‐enderby, Christopher K. Surratt 63 citations

The West African iboga plant has been used for centuries by the Bwiti and Mbiri tribes to induce hallucinations during religious ceremonies. Ibogaine, the principal alkaloid responsible for iboga's psychedelic properties, was isolated and sold as an antidepressant in France for decades before its adverse effects precipitated its removal from the market. An ibogaine resurgence in the 1960s was...

DOI: 10.1021/acschemneuro.8b00294 (opens in new tab) Hallucinogen Nicotine Synthetic cannabinoids Nicotinic acetylcholine receptor +2

Ibogaine: History, Pharmacology, Spirituality, & Clinical Data

Integrative Addiction and Recovery September 1, 2018 Benjamin Shapiro 1 citation

Abstract Ibogaine is an indole alkaloid derived from the African shrub Tabernathe iboga with broad anti-addictive, anti-depressant, and central nervous system stimulating effects. It is categorized as an oneriogen (or atypical hallucinogen) and has been used in West African tribal rituals for centuries. It was identified by French explorers in the early 1900s, came to the United States in the...

Cardiac arrest after ibogaine intoxication.

Journal of arrhythmia August 1, 2018 Christian Steinberg, Marc W Deyell 18 citations

Ibogaine is a psychoactive herbal medication with alleged antiaddiction properties. We report a case of ibogaine intoxication mimicking Long-QT syndrome resulting in ventricular flutter and nearby cardiac arrest. A 61-year-old man experienced massive QT prolongation and ventricular flutter at a rate of 270 beats per minute requiring defibrillation after ingestion of a large dose of Ibogaine....

DOI: 10.1002/joa3.12061 (opens in new tab) Full text (opens in new tab) Delayed qt recovery Drug‐induced qt prolongation Long‐qt Ventricular arrhythmia +7

Cytochrome P450 and O-methyltransferase catalyze the final steps in the biosynthesis of the anti-addictive alkaloid ibogaine from Tabernanthe iboga

Journal of Biological Chemistry July 20, 2018 Scott C. Farrow, Mohamed O. Kamileen, Jessica Meades et al. 55 citations

Monoterpenoid indole alkaloids are a large (∼3000 members) and structurally diverse class of metabolites restricted to a limited number of plant families in the order Gentianales. Tabernanthe iboga or iboga (Apocynaceae) is native to western equatorial Africa and has been used in traditional medicine for centuries. Howard Lotsof is credited with bringing iboga to the attention of Western...

DOI: 10.1074/jbc.ra118.004060 (opens in new tab) Full text (opens in new tab) Indole alkaloid Apocynaceae Pharmacology Biochemistry +4

A phenomenological investigation into the lived experience of ibogaine and its potential to treat opioid use disorders

Journal of Psychedelic Studies June 1, 2018 Thaddeus James Camlin, Donald Eulert, A. Thomas Horvath et al. 21 citations

This study examined the lived experience of individuals who underwent ibogaine treatment for an opioid use disorder. Semi-structured interview questions probed for potential changes in predetermined categories derived from a literature review. Participants' experiences with ibogaine were analyzed for commonalities and emergent themes. Categories that emerged revealed themes about subjective...

Understanding the Healing Potential of Ibogaine through a Comparative and Interpretive Phenomenology of the Visionary Experience

Anthropology of Consciousness March 1, 2018 James Rodger 20 citations

Abstract Ibogaine is a hallucinogenic alkaloid, derived from Tabernanthe iboga, a plant unique to the rainforests of West Africa. Its traditional use as an epiphanic sacrament in local magico‐religious practice inspired its appropriation by Western drug addicts by whom it is now hailed as both a catalyst of psychospiritual insight and an effective alleviator of cravings and withdrawal. While...

DOI: 10.1111/anoc.12088 (opens in new tab) Appropriation Religious experience Phenomenology philosophy Legitimacy +6

Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study.

The American Journal of Drug and Alcohol Abuse 2018 Geoffrey E Noller, Chris M Frampton, Berra Yazar-Klosinski 150 citations

The psychoactive indole alkaloid ibogaine has been associated with encouraging treatment outcomes for opioid dependence. The legal status of ibogaine in New Zealand provides a unique opportunity to evaluate durability of treatment outcomes. To examine longitudinal treatment effects over a 12-month period among individuals receiving legal ibogaine treatment for opioid dependence. This...

DOI: 10.1080/00952990.2017.1310218 (opens in new tab) Full text (opens in new tab) Legal availability Opioid dependence Opioid detoxification Psychedelics +4

Treatment of opioid use disorder with ibogaine: detoxification and drug use outcomes.

The American Journal of Drug and Alcohol Abuse 2018 Thomas Kingsley Brown, Kenneth Alper 156 citations

Ibogaine is a monoterpene indole alkaloid used in medical and nonmedical settings for the treatment of opioid use disorder. Its mechanism of action is apparently novel. There are no published prospective studies of drug use outcomes with ibogaine. To study outcomes following opioid detoxification with ibogaine. In this observational study, 30 subjects with DSM-IV Opioid Dependence (25 males, 5...

SLC6 Transporter Folding Diseases and Pharmacochaperoning.

Handbook of experimental pharmacology 2018 Michael Freissmuth, Thomas Stockner, Sonja Sucic 44 citations

The human genome encodes 19 genes of the solute carrier 6 (SLC6) family; non-synonymous changes in the coding sequence give rise to mutated transporters, which are misfolded and thus cause diseases in the affected individuals. Prominent examples include mutations in the transporters for dopamine (DAT, SLC6A3), for creatine (CT1, SLC6A8), and for glycine (GlyT2, SLC6A5), which result in...

DOI: 10.1007/164_2017_71 (opens in new tab) Full text (opens in new tab) Ibogaine Er export Folding diseases Heat-shock proteins +22

The Effects of Ibogaine on Uterine Smooth Muscle Contractions: Relation to the Activity of Antioxidant Enzymes.

Oxidative Medicine and Cellular Longevity 2018 Zorana Oreščanin-dušić, Nikola Tatalović, Teodora Vidonja Uzelac et al. 7 citations

Ibogaine is an indole alkaloid originally extracted from the root bark of the African rainforest shrub Tabernanthe iboga. It has been explored as a treatment for substance abuse because it interrupts drug addiction and relieves withdrawal symptoms. However, it has been shown that ibogaine treatment leads to a sharp and transient fall in cellular ATP level followed by an increase of cellular...

Changes in Withdrawal and Craving Scores in Participants Undergoing Opioid Detoxification Utilizing Ibogaine.

Journal of Psychoactive Drugs 2018 Benjamin Malcolm, Martin Polanco, Joseph P Barsuglia 64 citations

Opioid use disorder (OUD) is currently an epidemic in the United States (US) and ibogaine is reported to have the ability to interrupt opioid addiction by simultaneously mitigating withdrawal and craving symptoms. This study examined opioid withdrawal and drug craving scores in 50 participants with OUD undergoing a week-long detoxification treatment protocol with ibogaine. The Addiction...

DOI: 10.1080/02791072.2018.1447175 (opens in new tab) Full text (opens in new tab) Opiate Ibogaine treatment ibogaine Therapy Medication +8

Ibogaine Acute Administration in Rats Promotes Wakefulness, Long-Lasting REM Sleep Suppression, and a Distinctive Motor Profile.

Frontiers in Pharmacology 2018 Joaquín González, José P Prieto, Paola Rodríguez et al. 31 citations

Ibogaine is a potent psychedelic alkaloid that has been the focus of intense research because of its intriguing anti-addictive properties. According to anecdotic reports, ibogaine has been originally classified as an oneirogenic psychedelic; i.e., induces a dream-like cognitive activity while awake. However, the effects of ibogaine administration on wakefulness (W) and sleep have not been...

DOI: 10.3389/fphar.2018.00374 (opens in new tab) Full text (opens in new tab) Rem sleep Hallucinogens Psychedelics Ibogaine: ibogaine +7

Ibogaine Detoxification Transitions Opioid and Cocaine Abusers Between Dependence and Abstinence: Clinical Observations and Treatment Outcomes.

Frontiers in Pharmacology 2018 Deborah C. Mash, Linda Duque, Bryan Page et al. 109 citations

Ibogaine may be effective for transitioning opioid and cocaine dependent individuals to sobriety. American and European self-help groups provided public testimonials that ibogaine alleviated drug craving and opioid withdrawal symptoms after only a single dose administration. Preclinical studies in animal models of addiction have provided proof-of-concept evidence in support of these claims....

DOI: 10.3389/fphar.2018.00529 (opens in new tab) Full text (opens in new tab) Noribogaine Detoxification Opioid dependence Ibogaine therapy: ibogaine +4

A Mixed-Method Analysis of Persisting Effects Associated with Positive Outcomes Following Ibogaine Detoxification.

Journal of Psychoactive Drugs 2018 Alan K. Davis, Elise Renn, Austin-Marley Windham-Herman et al. 34 citations

We examined persisting effects, self-perceived challenges, and potential benefits associated with positive outcomes following ibogaine detoxification using data collected as part of a larger online retrospective study of 73 patients who received treatment for chronic opioid use in Mexico between 2012 and 2015. A mixed-methods design was used comparing treatment responders versus non-responders,...